Canada markets closed

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.7058-0.0942 (-2.48%)
At close: 04:00PM EDT

Inventiva S.A.

50 rue de Dijon
Daix 21121
33 3 80 44 75 00

Full Time Employees120

Key Executives

NameTitlePayExercisedYear Born
Mr. Frederic CrenCo-Founder, CEO & Chairman521.29kN/A1966
Dr. Pierre Broqua Ph.D.Co-Founder, Chief Scientific Officer, Deputy CEO & Director450.21kN/A1962
Mr. Jean VolatierDeputy GM & CFON/AN/A1965
Ms. Alice Roudot-Ketelers Pharm.D.Chief Operating OfficerN/AN/A1971
Mr. Eric Duranson L.L.M.General CounselN/AN/A1974
Ms. Nathalie HarroyHead of Human ResourcesN/AN/A1967
Dr. Michael CooremanChief Medical OfficerN/AN/A1958
Ms. Pascaline Clerc Ph.D.Executive Vice President of Strategy & Corporate AffairsN/AN/A1980
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Corporate Governance

Inventiva S.A.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.